5FA Stock Chart & Stats
€8.35
€0.00(0.00%)
At close: 4:00 PM EST
€8.35
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€7.20 - €9.25
Previous CloseN/A
Volume0.00
Average Volume (3M)160.00
Market Cap
€1.21B
Enterprise Value€903.22B
Total Cash (Recent Filing)€104.86B
Total Debt (Recent Filing)€661.52B
Price to Earnings (P/E)15.7
Beta0.16
Next Earnings
Nov 10, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)86.21
Shares Outstanding171,459,470
10 Day Avg. Volume480
30 Day Avg. Volume160
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.92
Price to Sales (P/S)0.38
P/FCF Ratio-32.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.52
Revenue Forecast (FY)€3.97B
Bulls Say, Bears Say
Bulls Say
Recurring Healthcare DemandExposure to dialysis and other chronic-care treatments creates repeat demand for consumables, while packaging and contract services broaden customer relationships. This mix can support durable healthcare revenue across hospitals, clinics, and drug manufacturers over the next several quarters.
Steady Revenue ExpansionRevenue has expanded materially over several years, indicating sustained top-line progress rather than reliance on a single reporting period. Continued growth across medical products, packaging, and services can improve operating leverage and strengthen Nipro’s scale with healthcare and pharmaceutical customers.
Improving Operating ProfitabilityThe year-over-year improvement in operating margin suggests that Nipro is retaining more revenue after operating costs, despite remaining modestly profitable overall. If maintained, better operating performance could support earnings resilience and gradually improve the company’s ability to fund investment internally.
Bears Say
Elevated LeverageDebt remains high relative to equity, leaving Nipro with less financial flexibility if margins weaken or investment needs rise. Although leverage has improved from FY2021, the current capital structure can constrain debt reduction, increase financing sensitivity, and limit future allocation choices.
Persistent Negative Free Cash FlowRepeated free-cash outflows indicate that reported earnings are not consistently converting into cash available for debt reduction or shareholder returns. Ongoing investment needs and/or working-capital pressure could therefore keep funding dependent on operating improvement or external financing.
Thin And Volatile ProfitabilityNipro’s bottom-line margin remains thin and has fluctuated meaningfully across recent fiscal years, leaving limited buffer against cost increases or weaker demand. Even with improved operating margin, modest net profitability reduces resilience and makes sustained cash generation more difficult.
Nipro News
5FA FAQ
What was Nipro Corporation’s price range in the past 12 months?
Nipro Corporation lowest stock price was €7.20 and its highest was €9.25 in the past 12 months.
What is Nipro Corporation’s market cap?
Nipro Corporation’s market cap is €1.21B.
When is Nipro Corporation’s upcoming earnings report date?
Nipro Corporation’s upcoming earnings report date is Nov 10, 2026 which is in 27 days.
How were Nipro Corporation’s earnings last quarter?
Nipro Corporation released its earnings results on Aug 10, 2026. The company reported €0.132 earnings per share for the quarter, beating the consensus estimate of €0.081 by €0.051.
Is Nipro Corporation overvalued?
According to Wall Street analysts Nipro Corporation’s price is currently Overvalued.
Does Nipro Corporation pay dividends?
Nipro Corporation does not currently pay dividends.
What is Nipro Corporation’s EPS estimate?
Nipro Corporation’s EPS estimate is 0.11.
How many shares outstanding does Nipro Corporation have?
Nipro Corporation has 171,459,470 shares outstanding.
What happened to Nipro Corporation’s price movement after its last earnings report?
Nipro Corporation reported an EPS of €0.132 in its last earnings report, beating expectations of €0.081. Following the earnings report the stock price went up 0.571%.
Which hedge fund is a major shareholder of Nipro Corporation?
Currently, no hedge funds are holding shares in DE:5FA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nipro Corporation
Nipro Corporation, along with its affiliated companies, operates across three primary business divisions: medical devices, pharmaceuticals, and pharmaceutical packaging. The company's Medical Device sector is dedicated to the development, production, and distribution of an extensive selection of disposable medical products. These offerings encompass specialized items for renal treatment, interventional procedures and anesthesia, injection and infusion therapies, dialysis, cardiopulmonary support, diabetes management, and cell culture applications. This division also markets products associated with artificial organs, as well as generic and kit-based medical supplies. Within its Pharmaceutical division, Nipro delivers innovative pharmaceutical combination products, such as dual chamber bags, pre-filled syringes, and half-type kits. It further extends its services through contract manufacturing for orally administered medications, injectable solutions, and topical preparations. The Pharma Packaging segment is focused on providing a comprehensive array of glass packaging solutions. This includes vials, ampoules, syringes, cartridges, and glass tubes. Additionally, this division manufactures glass forming machinery, glass bulbs for vacuum flasks, and various other essential pharmaceutical packaging components, such as rubber stoppers. An 'Other' business activity involves the provision of thermostable enzymes, which are vital for clinical chemistry applications. Nipro also offers business management services. Established in Osaka, Japan, in 1947, Nipro Corporation now serves a wide international customer base, spanning Japan, the Americas, Europe, and other regions across Asia.






